Lumida Wealth : Non-Consensus Invest Beyond the Ordinary

FSD: Jane Street

Episode Notes

In this FSD episode, the day's actual alpha comes first (go buy flowers, seriously), then it splits between two things worth thinking about. First, a health and longevity segment fresh off a cardiologist visit: why cardiovascular disease is the number one killer, the fork between insulin resistance and atherosclerosis, a carnivore-diet experiment that sent LDLs the wrong way, and the case for trying a PCSK9 inhibitor. Then the focus shifts to what's really driving this market: the factor "kill box" versus "reward box," why the winning move is front-running the quant flows at Jane Street, and how an AI-built breakout strategy became the best performer on the book.

• (00:00) 80s synth-pop, puns, and the flowers tip
• (02:30) Cardiology visit: cardiovascular disease as the top preventable killer
• (04:00) Insulin resistance vs atherosclerosis and the diet fork
• (06:00) The carnivore diet experiment and rising LDLs
• (08:00) The statin debate and trying a PCSK9 inhibitor
• (10:00) Exercise as the drug that would be worth more than Lilly or Nvidia
• (12:00) Longevity as an investing theme: senior living, travel and leisure, aging demographics
• (14:00) A Jane Street market and the factor kill box vs reward box
• (16:30) Front-running Jane Street and why it needs less capital than you'd think
• (18:00) The factor tools coming to the Lumida app
• (19:30) Communication sector setup for mean reversion
• (20:30) Momentum broadening away from semis, still holding DRAM
• (21:30) Buy stocks two weeks before earnings, and the bank setup for July
• (23:00) Why OpenAI's delayed IPO hurt Goldman and Morgan Stanley
• (24:00) Buy-the-dip research and the AI breakout-detection strategy
• (26:00) Why AI will be hugely disruptive to investing
• (27:30) Penthouse social event and a hello from his son

About the show: Non-Consensus Investing is Ram Ahluwalia's running commentary on markets, where he shares how he's actually positioning capital and talks through the ideas most investors are missing. Real-time analysis, specific names, and a bias toward what's overlooked rather than what's crowded.